ArticleJournal of nanobiotechnology2020
Hyaluronic acid-coated polymeric micelles with hydrogen peroxide scavenging to encapsulate statins for alleviating atherosclerosis.
Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 58 citations in OpenAlex.
- Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.Journal of biomedical science · 2026Review
- Natural Product-Based Nanomicelles: Properties, Fabrication Strategies, and Therapeutic Applications in Diseases.International journal of nanomedicine · 2026Review
- Advancements in dual-targeting nanoparticle strategies for enhanced atherosclerosis therapy: Overcoming limitations of single-targeting approaches.Bioactive materials · 2026Review
- Nanomedicines Against Mitochondrial Dysfunction-Induced Metabolic Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Nano-formulations in disease therapy: designs, advances, challenges, and future directions.Journal of nanobiotechnology · 2025Review
- Targeted drug delivery systems for atherosclerosis.Journal of nanobiotechnology · 2025Review
- Polymeric Nanomaterials for Atherosclerosis Diagnosis and Treatment.Polymer science & technology (Washington, D.C.) · 2025Review
- Application of Nanomaterials in Early Imaging and Advanced Treatment of Atherosclerosis.Chemical & biomedical imaging · 2025Review
- Silicosis: from pathogenesis to therapeutics.Frontiers in pharmacology · 2025Review
- Recent progress in ROS-responsive biomaterials for the diagnosis and treatment of cardiovascular diseases.Theranostics · 2025Review
- Nano Delivery System for Atherosclerosis.Journal of functional biomaterials · 2024Review
- Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis.Molecules (Basel, Switzerland) · 2024Review
- Advances in the treatment of atherosclerosis with ligand-modified nanocarriers.Exploration (Beijing, China) · 2024Review
- Polymeric Nanoparticles for Drug Delivery.Chemical reviews · 2024Review
- The Advancement and Obstacles in Improving the Stability of Nanocarriers for Precision Drug Delivery in the Field of Nanomedicine.Current topics in medicinal chemistry · 2024Review
- Advances in drug delivery to atherosclerosis: Investigating the efficiency of different nanomaterials employed for different type of drugs.Materials today. Bio · 2023Review
- Advances in treatment strategies based on scavenging reactive oxygen species of nanoparticles for atherosclerosis.Journal of nanobiotechnology · 2023Review
- Advances in imaging and treatment of atherosclerosis based on organic nanoparticles.APL bioengineering · 2022Review
- Biosensor-Integrated Drug Delivery Systems as New Materials for Biomedical Applications.Biomolecules · 2022Review
- Self-oxygenation mesoporous MnOJournal of nanobiotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Inflammation and oxidative stress are two major factors that are involved in the pathogenesis of atherosclerosis. A smart drug delivery system that responds to the oxidative microenvironment of atherosclerotic plaques was constructed in the present study. Simvastatin (SIM)-loaded biodegradable polymeric micelles were constructed from hyaluronic acid (HA)-coated poly(ethylene glycol)-poly(tyrosine-ethyl oxalyl) (PEG-Ptyr-EO) for the purpose of simultaneously inhibiting macrophages and decreasing the level of reactive oxygen species (ROS) to treat atherosclerosis. HA coating endows the micelle system the ability of targeting CD44-positive inflammatory macrophages. Owing to the ROS-responsive nature of PEG-Ptyr-EO, the micelles can not only be degraded by enzymes, but also consumes ROS by itself at the pathologic sites, upon which the accumulation of pro-inflammatory macrophages is effectively suppressed and oxidative stress is alleviated. Consequently, the cellular uptake experiment demonstrated that SIM-loaded HA-coated micelles can be effectively internalized by LPS-induced RAW264.7 cells and showed high cytotoxicity against the cells, but low cytotoxicity against LO2 cells. In mouse models of atherosclerosis, intravenously SIM-loaded HA-coated micelles can effectively reduce plaque content of cholesterol, resulting in remarkable therapeutic effects. In conclusion, the SIM-loaded micelle system provides a promising and innovative option against atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.